- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05337696
Circumferential Vertebral Reconstruction of Osteoporotic Compression Fractures Using a Novel Bipedicular Peek Implant (RECONSTRUCT)
Study Overview
Status
Intervention / Treatment
Detailed Description
Vertebral compression fractures affect an estimated 1.4 million patients in the world annually and incidence rates rise exponentially with age, especially in women. Outcomes following non-interventional management of these injuries are generally poor, largely as a consequence of opioid requirements, prolonged immobilization, and bedrest. As a result, interventional techniques such as balloon kyphoplasty and vertebroplasty with or without implantable devices are currently regarded as the standard of care for select patients with acute painful osteoporotic compression fractures. These procedures relieve fracture pain by stabilizing the fracture site using cement.
Alternative interventional techniques include percutaneous vertebral augmentation, which combine cement injection with implantable devices, such as the SpineJack® and KIVA® devices. The RECONSTRUCT study will build on the outcomes of the SAKOS and KAST clinical trails that evaluated the SpineJack® and KIVA® devices, respectively.
The Vertebral Implant PEEK (VIP) implant (V-STRUT© manufactured by Hyprevention) has undergone both clinical and pre-clinical testing. Static and dynamic bending of the implant has been evaluated to demonstrate that the product is capable of supporting in-situ loading, and increase fracture load and energy to fracture.
A total of 30 eligible subjects with a diagnosis of osteoporotic fractures of the thoracolumbar spine, as confirmed by MRI scan, and who are treated with the Vertebral Implant PEEK (VIP) device will be asked to join the study. No placebo or control will be utilized during this study.
RECONSTRUCT has been designed with the intention of achieving two goals: 1) to inform the design of larger controlled clinical trials in the future and 2) to assess the safety of the study device within the patient sample.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Sydney Edwards
- Phone Number: 212 241 2524
- Email: sydney.edwards@mountsinai.org
Study Contact Backup
- Name: Sukaina Davdani
- Phone Number: 212 241 2524
- Email: Sukaina.Davdani@mountsinai.org
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Not yet recruiting
- Johns Hopkins
-
Contact:
- Majid Khan
-
Principal Investigator:
- Majid Khan
-
-
New York
-
New York, New York, United States, 10029
- Recruiting
- Icahn School of Medicine at Mount Sinai
-
Contact:
- Michael T Caton
-
Principal Investigator:
- Michael T Caton
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, United States, 18015
- Recruiting
- St. Luke's
-
Contact:
- Martin Oselkin
-
Principal Investigator:
- Martin Oselkin
-
-
West Virginia
-
Morgantown, West Virginia, United States, 26506
- Recruiting
- West Virginia
-
Contact:
- SoHyun Boo
-
Principal Investigator:
- SoHyun Boo
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 50
- Osteoporotic compression fractures of the thoracolumbar spine (T9 -L5)
- Fracture age of ≤ 8 weeks as indicated by onset of pain or known antecedent traumatic event with corresponding evidence of acuity on MRI (T1 and STIR sequences) or radioisotope bone scan
- ODI ≥ 30/100 at screening visit and VAS ≥ 60 at screening visit
- Failure of conservative management strategies for compression fractures resulting in inadequately controlled pain and/or patient immobility
Patient has failed non-operative medical therapy as defined by one of the following definitions set forth by the American College of Radiology:
- For a patient rendered nonambulatory as a result of pain from a VCF, pain persisting at a level that prevents ambulation despite 24 hours of analgesic therapy; or
- For a patient with sufficient pain from a VCF such that physical therapy is intolerable, pain persisting at that level despite 24 hours of analgesic therapy; or
- For a patient with pain from a VCF, unacceptable side effects such as excessive sedation, confusion, or constipation as a result of the analgesic therapy necessary to reduce pain to a tolerable level.
- Magerl classification A1.1, A1.2, A1.3, A2.1, A2.2 and A3.1 type fractures
- Appropriate pedicle diameter to receive 5.5mm diameter or 6.5mm diameter implants
- ASA < 4
Exclusion Criteria:
- Patient clearly improving on conservative treatment
- Any contra-indication or allergy to implant material or cement
- Systemic infection or infection located in the spine
- Any medical condition including but not limited to anemia, coagulation disorders, fibromyalgia, algoneurodystrophy, Paget's disease, uncontrolled diabetes that would preclude the patient from having surgery or would impede the benefit of surgery
- Neurologic signs or symptoms related to the fracture or the impeding pathological fracture
- Any previous surgical treatment (material or cement) in the targeted vertebra
- Less than one third of the original vertebral body height remaining
- Unstable fractures or neoplasms with posterior involvement
- Damages of the pedicles or posterior wall
- Sclerotic cancellous bone
- Pedicles not large enough to accept V-STRUT© instrumentation and implants
- Pregnancy(women of childbearing potential must have a negative pregnancy test to participate)
- Pre-existing or clinically unstable neurologic deficit
- Spinal canal compromise causing clinical manifestations of cord, neural foramen, or nerve root compression at the level to be treated
- Any physical exam evidence of myelopathy or radiculopathy
- Pain based on clinical diagnosis of herniated nucleus pulposus or severe spinal stenosis (progressive weakness or paralysis)
- Bedbound prior to incident fracture
- Any radiographic evidence of pedicle fracture visible on pre-operative imaging
- Spondylolisthesis >Grade 1 at target VB
- Any underlying systemic bone disease other than osteoporosis (e.g., osteomalacia, osteogenesis imperfect, Paget's disease, etc.)
- A medical contraindication to spinal surgery and/or general anesthesia, such as coagulopathy and/or taking warfarin (Coumadin) or other anticoagulant or anti-aggregate (anti-platelet agents) on regular basis for coagulopathy (with a threshold for normal being INR≤1.5, PTT within lab normal range, and platelet count > 100,000)
- Disabling backpain due to causes other than acute fracture
- Severe cardiopulmonary deficiencies
- Any evidence of alcohol or drug abuse
- Uncontrolled psychiatric illness or severe dementia
- Involved in medical litigation including workers' compensation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Participants with vertebral compression fractures
Participants with vertebral compression fractures who have failed conservative care strategies.
|
Vertebral Implant PEEK (VIP) procedure is a minimally invasive/percutaneous vertebral augmentation (PVA), image guided procedure.
Two VIP devices are implanted in each to be treated vertebra.
A cavity is drilled allowing the introduction of the implant posteriorly through the pedicle and the vertebral body upto the anterior wall.
A part of the implant is embedded into the pedicle, thus providing posterior support.
The other part of the device, located in the vertebral body, presents a central canula and lateral perforations, which allow acrylic bone cement diffusion, filling of the vertebral body, filling and fixing the implant, and supporting of the upper endplate.
The combination of the implant and the cement allows the treatment of vertebral fractures.
Other Names:
The study device is V-STRUT© Vertebral Implant manufactured by Hyprevention (VIP -Vertebral Implant PEEK), FDA cleared under K191709, indicated for use in the treatment of vertebral fractures in the thoracic and lumbar spine from T9 to L5.
It is intended to be used in combination with PMMA bone cement.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of adverse events
Time Frame: End of study at 18 months
|
Safety will be measured by number of device related serious adverse events using Common Terminology Criteria for Adverse Events (CTCAE) v4.0
|
End of study at 18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Procedure duration
Time Frame: Day 1, at end of procedure
|
Procedure duration in minutes
|
Day 1, at end of procedure
|
Volume of cement injected
Time Frame: Day 1, at end of procedure
|
volume of cement injected per level
|
Day 1, at end of procedure
|
Cement leakage
Time Frame: Day 1, at end of procedure
|
Presence of cement leakage
|
Day 1, at end of procedure
|
Fluoroscopy time
Time Frame: Day 1, at end of procedure
|
Day 1, at end of procedure
|
|
Fluoroscopy dose
Time Frame: Day 1, at end of procedure
|
Day 1, at end of procedure
|
|
Vertebral Height
Time Frame: 6 months
|
percentage of vertebral height restoration
|
6 months
|
Visual Analogue Symptom (VAS)
Time Frame: 6 months
|
Pain VAS, full range from 0-100, with higher score indicating more pain
|
6 months
|
The Oswestry Disability Index
Time Frame: 6 months
|
The Oswestry Disability Index is a Low Back Pain Disability Questionnaire frequently used to assess function and very often report in the literature.
Full range from 0-100, with higher score indicating more severe disability.
|
6 months
|
Lost to follow up rate
Time Frame: 6 months
|
Study will evaluate the lost to follow up rate to determine statistical methodology and enrollment requirements for any follow up pivotal study
|
6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Reade De Leacy, MD, Icahn School of Medicine at Mount Sinai
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY-21-01269
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Upon the completion of the study, Mount Sinai's data management team will clean and analysis all data in preparation of manuscript writing and publication. The intention will be to publish together between the principal investigator and the sponsor.
Following publication, Mount Sinai will archive and store all associated data on it's cloud-based system
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vertebral Compression Fractures
-
Optimus Clinical ResearchCareFusionCompletedVertebral Compression Fractures | Osteoporotic Vertebral Compression Fractures | Acute Vertebral FracturesAustralia
-
AgNovos Healthcare, LLCRecruitingVertebral Fracture | Vertebral Compression Fracture | Vertebral CompressionGermany, Spain
-
AgNovos Healthcare, LLCRecruitingVertebral Compression Fracture | Vertebral Compression | Compression FractureUnited States
-
Stryker InstrumentsTalosixActive, not recruiting
-
University of VirginiaCook Group Incorporated; ArthroCare Corporation; Cardinal HealthCompletedOsteoporotic Vertebral Compression FracturesUnited States
-
Jaseng Medical FoundationRecruitingVertebral Compression Fracture | Vertebral Compression | Korean Traditional Medicine | Integrative Korean MedicineKorea, Republic of
-
Wiltrom Co., Ltd.Maxis Medical GmbHRecruitingOsteoporotic Vertebral Compression FracturesGermany
-
HypreventionCompletedVertebral Compression FractureFrance
-
University Hospital TuebingenUnknown
-
Medtronic Spine LLCCompletedVertebral Body Compression Fractures (VCFs)Germany, United States, Belgium
Clinical Trials on Vertebral Implant PEEK Procedure
-
Cairo UniversityCompleted
-
Stryker CraniomaxillofacialQmed Consulting A/SEnrolling by invitationCraniofacial Abnormalities | Cranioplasty | Craniofacial InjuriesGermany, Spain, United States, Austria, France, United Kingdom
-
Mansoura UniversityCompleted
-
Boston Scientific CorporationRecruitingCardiac DiseaseFrance, Spain, Italy, Belgium, Germany, Greece, Israel, United Kingdom, Ireland
-
University Hospital, RouenMicroPort CRMUnknownCardiac Resynchronisation TherapySpain, France
-
University Hospital, RouenMicroPort CRMCompletedCardiac Resynchronisation TherapyFrance
-
University Health Network, TorontoWomen's College Hospital; Canadian Breast Cancer Foundation; Vancouver General... and other collaboratorsCompleted
-
Cairo UniversityUnknown
-
Neurotech PharmaceuticalsThe Emmes Company, LLC; The Lowy Medical Research Institute LimitedCompletedMacular Telangiectasia Type 2United States, Australia
-
University of LouisvilleJames Graham Brown Cancer CenterTerminatedVertebral MetastasisUnited States